research use only
Cat.No.S7525
| Related Targets | p38 MAPK Raf JNK MEK Ras KRas S6 Kinase MAP4K TAK1 Mixed Lineage Kinase |
|---|---|
| Other ERK Inhibitors | Ravoxertinib (GDC-0994) Ulixertinib (BVD-523) SCH772984 LY3214996 (Temuterkib) FR 180204 VX-11e AZD0364 (ATG-017) ERK5-IN-1 Senkyunolide I MK-8353 (SCH900353) |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| human HeLa cells | Function assay | Inhibition of EGF-induced BMK1 autophosphorylation in human HeLa cells by SDS-PAGE analysis, IC50=0.24 μM | ||||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 80 mg/mL
(168.58 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 474.55 | Formula | C26H30N6O3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1234480-50-2 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CCOC1=C(C=CC(=C1)N2CCC(CC2)O)NC3=NC=C4C(=N3)N(C5=CC=CC=C5C(=O)N4C)C | ||
| Targets/IC50/Ki |
BMK1
(Cell-free assay) 80 nM(Kd)
BRD4 (1)
(Cell-free assay) 170 nM(Kd)
|
|---|---|
| In vitro |
XMD8-92, via inhibition of BMK1 activation, significantly induces p21 expression in cells, and mediates suppression of cancer cell proliferation. This compound markedly abrogates the inhibitive effects of hydroxysafflor yellow A (HSYA) on hepatic stellate cell (HSC) activation, and blockes the HSYA-mediated MEF2C down-regulation. |
| In vivo |
XMD8-92 (50 mg/kg i.p.) significantly inhibit the growth of the xenografted human or syngeneic mouse tumors by blocking tumor cell proliferation and tumor-associated angiogenesis. This compound inhibits pancreatic tumor xenograft growth by significant downregulation of DCLK1 and several of its downstream targets. |
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | p53 BMK1 / p-BMK1 |
|
22869143 |
| Immunofluorescence | MDM2 |
|
22869143 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.